Scientists at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have disclosed benzofuran compounds targeting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) acting as RAF proto-oncogene serine/threonine-protein kinase (RAF-1; c-Raf) inhibitors reported to be useful for the treatment of cancer.
Prostate cancer (PC), often referred to as a cold tumor, typically presents a poor immune response, making it difficult for immune-based therapies to be effective. Metastatic castration-resistant PC (mCRPC) presents a highly aggressive phenotype often refractory to systemic treatment.
Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
Shanghai Apeiron Biotechnology Co. Ltd. has divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and Kartagener syndrome (primary ciliary dyskinesia).
Haisco Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an androgen receptor (AR) targeting moiety acting as AR degradation inducers reported to be useful for the treatment of prostate cancer.
Astrazeneca AB has synthesized antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to cytotoxic moieties through enzymatically cleavable linkers reported to be useful for the treatment of cancer.
Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of colorectal cancer.
Sarcomas are generally classified into soft tissue sarcomas, such as fibrosarcoma, and bone sarcomas such as chondrosarcoma, which are rare cancers in adults accounting for about 1% of all cancer diagnoses, while in children the rate goes up to 20% of all cancer cases.
Calidi Biotherapeutics Inc. has released promising preclinical results for its systemic Rtnova platform showing its ability to successfully deliver transient gene therapy payloads to targeted tumors. Moreover, the company’s tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.
Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different mechanisms are advancing in the oncologic pipeline. Researchers from Cybrexa Therapeutics Inc. presented new preclinical data on CBX-15, a peptide-drug conjugate (PDC) consisting of a pH-low insertion peptide (pHLIP) linked to monomethyl auristatin E (MMAE).
RSS
